此外，鉴于股份购回计划及现有购回授权的现时运用情况，董事会拟更新现有购回授权，以不时获准购 回更多股份。公司将召开股东特别大会，以寻求股东批准更新及修订现有购回授权。 智通财经APP讯，酷派集团(02369)发布公告，为促进公司可持续经营及发展，保障投资者长远利益，并 实现股东价值最大化，董事会经充分考虑公司现时经营状况、财务状况及未来发展前景后，谨此宣布其 已议决视市况进一步于公开市场购回股份，但每股股份的实际购回价格不得高于紧接每次购回前五个交 易日的股份平均收市价的5%(包括5%)。公司管理团队对集团前景充满信心。股份购回计划反映董事会 及管理团队对公司长远业务前景及增长的信心。董事会认为股份购回计划符合公司及其股东的整体最佳 利益。 ...

智通财经APP讯，国际商业结算(00147)发布公告，作为集团投资加密货币及相关业务发展规划的一部 分，于2025年10月16日，董事会决议建议按董事认为适当的时间及价格，于本公布日期起计两个月期间 内进一步收购比特币。可能收购事项应付的总代价不得超过2亿港元，该金额乃参考集团财务状况而厘 定。 ...

Core Viewpoint - The company has reported a significant turnaround in its photovoltaic materials business, achieving profitability in the third quarter of 2025 compared to losses in the same period last year [1][2]. Financial Performance - The unaudited profit for the photovoltaic materials segment during the period from July 1, 2025, to September 30, 2025, is approximately RMB 960 million, which includes a post-tax gain of RMB 640 million from the sale of an associate [1]. - The adjusted EBITDA for the same segment is approximately RMB 1.41 billion, marking a recovery from the previous year's adjusted LBITDA [1]. - The average external selling price of granular silicon (including tax) is RMB 42.12 per kilogram, while the average production cash cost is RMB 24.16 per kilogram, including R&D costs [1]. Industry Positioning - The company is recognized as a transformer in the polysilicon industry and a leader in the new quality productivity of the nation [1]. - The company utilizes advanced silane fluidized bed technology, which provides a significant energy consumption advantage, aligning with the new mandatory national standards for energy consumption limits for polysilicon and germanium products [1]. - The company is committed to overcoming the challenges of "involution" and unhealthy competition in the polysilicon industry by enhancing collaboration with upstream and downstream partners to achieve a win-win situation across the industry chain [2].

Core Viewpoint - China Hengyouyuan Group (08128) announced a share buyback plan, intending to repurchase 1 million shares at a cost of 40 million Hong Kong dollars on October 16, 2025 [1] Group 1 - The company plans to spend 40 million Hong Kong dollars for the buyback [1] - The buyback involves repurchasing 1 million shares [1] - The execution date for the buyback is set for October 16, 2025 [1]

智通财经APP讯，中国恒有源集团(08128)发布公告，于2025年10月16日，该公司斥资4万港元回购100万 股。 ...

Core Viewpoint - East Asia Bank celebrates its 40th anniversary of operations in Shenzhen, highlighting its commitment to the development of the Greater Bay Area and its strategic expansion in cross-border financial services [1][3]. Group 1: Company Milestones - East Asia Bank established a representative office in Shenzhen in 1985 and upgraded it to a branch in 1987, marking over a century of service in the mainland market [1]. - The opening of the Futian flagship branch enhances East Asia China's network in Shenzhen, strategically located near the Futian High-Speed Railway Station [1][5]. Group 2: Strategic Focus - The Greater Bay Area is central to East Asia Bank's development strategy, with a network covering all "9+2" cities in the region [1]. - The bank has established a strategic network in Shenzhen with six major outlets, serving key financial and technological innovation areas [1][5]. Group 3: Leadership Insights - The Co-CEO of East Asia Bank emphasized the bank's role as one of the first foreign banks in Shenzhen, actively participating in the development of the Special Economic Zone [3]. - The Vice CEO and Executive Director of East Asia China noted the importance of the Futian flagship branch in expanding the bank's presence in Shenzhen [5].

格隆汇10月16日丨欧化(01711.HK)公告，于2025年10月16日，公司与英皇国际及AY产业控股订立2025 年总租赁协议，以规管(i)集团与英皇国际集团；及(ii)集团与AY集团之间有关租赁交易的安排，自2025 年10月1日起至2027年3月31日止。 于公告日期，集团成员公司向英皇国际集团及AY集团租赁下列位于香港之物业：(a)位于香港湾仔轩尼 诗道288号英皇集团中心之一个办公室单位；(b)位于香港九龙红磡漆咸道北275号蔚景楼之一个零售店 铺；(c)位于香港北角英皇道560号健威坊之一个零售店铺；(d)位于新界屯门屯利街2号新都商场之一个 零售店铺；(e)位于新界屯门屯利街2号新都商场之一个灯箱；及(f)位于新界屯门新安街15号山龄工业大 厦之一个仓库 目前由(i)集团成员公司为租户与(ii)英皇国际集团及/或AY集团为业主就以上物业已订立六份租赁／租约 ／特许协议。该等租赁最早的届满日期为2026年3月31日，最迟的届满日期为2026年12月31日。每月租 金介乎28,500港元至330,000港元，而物业建筑面积介乎856平方尺至57,000平方尺。租期一般为六个月 至三年； 集团目前向 ...

风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何 意见、观点或结论是否符合其特定状况。据此投资，责任自负。 据报道，到2030年，OpenAI在甲骨文服务器上的支出可能会超过在微软服务器上的支出。 ...

天虹国际集团(02678)公布，2025年10月16日耗资33.5万港元回购7.35万股股份。 ...

Core Viewpoint - The company has entered into a global exclusive licensing agreement with Dianthus Therapeutics to advance the clinical asset LBL-047, a novel anti-BDCA2-TACI bispecific fusion protein, which has received IND approval in the US and acceptance in mainland China [1][2]. Group 1: Licensing Agreement Details - The agreement grants Dianthus exclusive rights to develop, manufacture, and commercialize LBL-047 outside of Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan [1]. - The company will receive an upfront payment of up to $38 million, along with potential milestone payments totaling up to $1 billion related to clinical development, regulatory, and commercialization achievements [1]. - The company will also earn tiered royalties on net sales outside of Greater China, with rates ranging from single digits to low double digits [1]. Group 2: Strategic Importance - The collaboration with Dianthus, recognized for its leadership in developing transformative therapies for severe autoimmune diseases, is expected to enhance the company's commitment to advancing innovative drug candidates into clinical stages [2]. - The agreement aligns with the overall best interests of the company and its shareholders [2]. Group 3: Mechanism and Potential of LBL-047 - LBL-047 targets BAFF/APRIL and BDCA2, aiming to simultaneously inhibit the activity of plasmacytoid dendritic cells (pDC) and the differentiation and activation of B cells and plasma cells [3]. - The drug shows strong therapeutic potential for autoimmune diseases such as systemic lupus erythematosus (SLE), dermatomyositis, IgA nephropathy (IgAN), and Sjögren's syndrome [3]. - LBL-047 is designed with glycosylation modifications to enhance its efficacy and broaden its immunosuppressive effects, while Fc region modifications extend its half-life, reducing dosing frequency and improving patient compliance [3].